Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
Abstract Introduction Multiple antiretroviral agents have demonstrated efficacy for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP). As a result, clinical trials of novel agents have transitioned from placebo‐ to active‐controlled designs; however, active‐controlled trials do not...
Main Authors: | Deborah Donnell, Fei Gao, James P. Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Srilatha Edupuganti, Nyaradzo Mgodi, Helen Rees, Jared M. Baeten, Glenda Gray, Linda‐Gail Bekker, Mina Hosseinipour, Sinead Delany‐Moretlwe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-06-01
|
Series: | Journal of the International AIDS Society |
Subjects: | |
Online Access: | https://doi.org/10.1002/jia2.26118 |
Similar Items
-
Pre-exposure prophylaxis (PrEP) efficacy to reduce HIV/AIDS incidence rate among male sex to male (MSM) in Asia
by: Prayogi Miura-Susanto
Published: (2023-01-01) -
Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)
by: Zheng Wan, et al.
Published: (2024-01-01) -
Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC)
by: Mitchell Warren, et al.
Published: (2023-07-01) -
Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro
by: Bethany S. Schneiderman, et al.
Published: (2022-04-01) -
Vitamin D and Calcium Supplementation Reverses Tenofovir-Caused Bone Mineral Density Loss in People Taking ART or PrEP: A Systematic Review and Meta-Analysis
by: Xiaoyan Bi, et al.
Published: (2022-03-01)